Chasity Brock
Family · Bremen, GANPI 1407291925
Payments from drug & device makers
Across 449 payments — averaging $16.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Novo Nordisk$988
- Pfizer$806
- Lilly USA, LLC$510
- Amgen$456
- AstraZeneca$270
- plus $2K from 33 others
What the payments were for
- Food & beverage$7,521100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,521 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 99 | $123,136 |
| OzempicSemaglutide | 63 | $102,397 |
| JardianceEmpagliflozin | 67 | $77,075 |
| VraylarCariprazine Hcl | 39 | $60,370 |
| RybelsusSemaglutide | 24 | $39,532 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $23,805 |
| LinzessLinaclotide | 21 | $21,555 |
| EliquisApixaban | 21 | $19,270 |
| Repatha SureclickEvolocumab | 20 | $16,240 |
| MyrbetriqMirabegron | 17 | $14,751 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 17 | $13,697 |
| UbrelvyUbrogepant | 13 | $13,515 |
| TrulicityDulaglutide | 12 | $11,068 |
| GemtesaVibegron | 12 | $5,739 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 162 | $4,789 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $988 | $141,92987 claims |
| GSKTrelegy Ellipta | $232 | $123,13699 claims |
| AbbVieVraylar, Linzess, Ubrelvy, Synthroid | $2,233 | $96,79386 claims |
| Boehringer IngelheimJardiance, Trijardy Xr | $58 | $90,77284 claims |
| AstraZenecaBreztri Aerosphere | $270 | $23,80519 claims |
| PfizerEliquis | $806 | $19,27021 claims |
| Astellas Pharma US IncMyrbetriq | $250 | $14,75117 claims |
| Lilly USA, LLCTrulicity | $510 | $11,06812 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $30 | $5,73912 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $3,353289 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.
Other family in Bremen
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.